|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Jaundice associated pruritis:A review of pathophysiology and treatment显示文摘To review the underlying pathophysiology and currently available treatments for pruritis associated with jaundice.English language literature was reviewed using MEDLINE,Pub Med,EMBASE and clinicaltrials.gov for papers and trails addressing the pathophysiology and potential treatments for pruritis associated with jaundice.Recent advances in the understanding of the peripheral anatomy of itch transmission have defined a histamine stimulated pathway and a cowhage stimulated pathway with sensation conveyed centrally via the contralateral spinothalamic tract.Centrally,cowhage andhistamine stimulated neurons terminate widely within the thalamus and sensorimotor cortex.The causative factors for itch in jaundice have not been clarified although endogenous opioids,serotonin,steroid and lysophosphatidic acid all play a role.Current guidelines for the treatment of itching in jaundice recommend initial management with biliary drainage where possible and medical management with ursodeoxycholic acid,followed by cholestyramine,rifampicin,naltrexone and sertraline.Other than biliary drainage no single treatment has proved universally effective.Pruritis associated with jaundice is a common but poorly understood condition for which biliary drainage is the most effective therapy.Pharmacological therapy has advanced but remains variably effective. | Ramez Bassari Jonathan B Koea | 2015 | World Journal of Gastroenterology2015，21，5： | 5 |
| 2 | Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies,chronic granulomatous disease,or AIDS显示文摘 | Caillot D Bassaris H McGeer A | | 0，，： | 1 |
| 3 | Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies,chronic granulomatous disease,or AIDS显示文摘 | Caillot D Bassaris H McGeer A | 2001 | Clin Infect Dis2001，33，8： | 1 |
| 4 | Pro-versus anti-inflammatory cytokine predfile in patients with severe sepsis:a market for prognosis and future the rapeutic options显示文摘 | Gogos CA Drosou E Bassaris HP | 2000 | J Infect Dis2000，181，2： | 1 |
| 5 | Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergllosis in patients with hematologic malignancies,chronic granulomatous disrase,or AIDS显示文摘 | Caillot D Bassaris H McGeer A | 2001 | Clin Infect Dis2001，33，： | 1 |
| 6 | Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease or AIDS显示文摘 | Caillot D Bassaris H McGeer A | 2001 | Clin Infect Dis2001，3，： | 1 |
| 7 | Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies,chronic granulomatous disease,or AIDS显示文摘 | Caillot D Bassaris H McGeer A | 2001 | Clin Infect Dis2001，33，： | 1 |
| 8 | Pro- versus anti -inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic op- tions 显示文摘 | Gogos CA Drosou E Bassaris HP | 2000 | J Infect Dis2000，181，1： | 1 |
| 9 | Pro-versus antiinflammatoIy cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options 显示文摘 | Gogos cA Dmsou E Bassaris HP | 2000 | J Infect Dis2000，181，1： | 1 |
| 10 | Cytokinc production and hospital mor- tality in patients with sepsis-induced stress hyperglycemia 显示文摘 | Leonidou L Mouzaki A Michalaki M DeLastie AL Kyriazopou- lou V Bassaris HP | 2007 | J Infect2007，55，： | 1 |
| 11 | Efficacy, safety and pharmacokinetics of intravenous followed by oral itraconazole in patients with invasive pulmonary aspergillosis 显示文摘 | Caillot D Bassaris H Seifert WF | 1999 | Antimicrob Agents Chemother1999，9，： | 1 |
| 12 | Pro-versus anti- inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options显示文摘 | Gogos CA Drosou E Bassaris HP | 2000 | J Infect Dis2000，181，1： | 1 |
| 13 | Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the the treatment of acute exacerbations of chronic bronchitis显示文摘 | Starakis I Gogos CA Bassaris H | 2004 | Int J Antimicrob Agets2004，23，1： | 1 |
| 14 | Five-day moxifloxacin th-erapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis显示文摘 | Starakis I Gogos CA Bassaris H | 2004 | Int J Antimicrob Agents2004，23，： | 1 |
| 15 | Proversus anti- inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options显示文摘 | Gogos CA Drosou E Bassaris HP | 2000 | J Infect Dis2000，181，1： | 1 |
| 16 | Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options 显示文摘 | Gogos CA Drosou E Bassaris HP | 2000 | J Infect Dis2000，181，1： | 1 |
| 17 | Pro-versus anti-inflamm-atory cytokine profile in patients with severe sepsis:a marker forprognosis and future therapeutic options显示文摘 | Gogos CA Drosou E Bassaris HP | 2000 | J Infect Dis2000，181，1： | 1 |
| 18 | Pro - versus anti - inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options显示文摘 | Gogos CA Droson E Bassaris HP | 2000 | J Infect Dis2000，181，1： | 1 |
| 19 | Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies,chronic granulomatous disease,or AIDS显示文摘 | Caillot D Bassaris H McGeer A | 2001 | Clin Infect Dis2001，33，： | 1 |
| 20 | Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy forthe treatment of acute exacerbation of chronic bronchitis 显示文摘 | Starakis I Cngos CA Bassaris H | 2004 | Int Antimicrob Agents2004，23，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员